


World Journal of *Gastroenterology*

World J Gastroenterol 2017 November 21; 23(43): 7653-7812



**EDITORIAL**

- 7653 Noncoding RNAs as drivers of the phenotypic plasticity of oesophageal mucosa

Fassan M, Facchin S, Munari G, Fanelli GN, Lorenzon G, Savarino E

MINIREVIEWS

- 7657 Functional interaction of endoplasmic reticulum stress and hepatitis B virus in the pathogenesis of liver diseases

Kim SY, Kyaw YY, Cheong J

- 7666 Pathological process of liver sinusoidal endothelial cells in liver diseases

Ni Y, Li JM, Liu MK, Zhang TT, Wang DP, Zhou WH, Hu LZ, Lv WL

ORIGINAL ARTICLE**Basic Study**

- 7678 Resveratrol modifies biliary secretion of cholephilic compounds in sham-operated and cholestatic rats

Dolezelova E, Prasnicka A, Cermanova J, Carazo A, Hyrsova L, Hroch M, Mokry J, Adamcova M, Mrkvicova A, Pavek P, Micuda S

- 7693 Chitinase 3-like 1 secreted by peritumoral macrophages in esophageal squamous cell carcinoma is a favorable prognostic factor for survival

Xing S, Zheng X, Zeng T, Zeng MS, Zhong Q, Cao YS, Pan KL, Wei C, Hou F, Liu WL

- 7705 Palmitate induces fat accumulation by activating C/EBP β -mediated G0S2 expression in HepG2 cells

Zhao NQ, Li XY, Wang L, Feng ZL, Li XF, Wen YF, Han JX

Retrospective Cohort Study

- 7716 Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016

Cheung KS, Seto WK, Fung J, Mak LY, Lai CL, Yuen MF

Retrospective Study

- 7727 Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis

Wang L, Hong Y, Wu J, Leung YK, Huang Y

- 7735 Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus

Zhang ZH, Liu QX, Zhang W, Ma JQ, Wang JH, Luo JJ, Liu LX, Yan ZP

- 7746** Procedure-related complications in gastric variceal obturation with tissue glue

Guo YE, Miao HB, Wen ZF, Xuan JY, Zhou HX

- 7756** Gastric xanthelasma and metabolic disorders: A large retrospective study among Chinese population

Chen Y, He XJ, Zhou MJ, Li YM

Clinical Trials Study

- 7765** Application of superb microvascular imaging in focal liver lesions

He MN, Lv K, Jiang YX, Jiang TA

Observational Study

- 7776** Chronic liver disease is universal in children with biliary atresia living with native liver

Lee WS, Ong SY, Foo HW, Wong SY, Kong CX, Seah RB, Ng RT

Prospective Study

- 7785** How severe is moderately severe acute pancreatitis? Clinical validation of revised 2012 Atlanta Classification

Ignatavicius P, Gulla A, Cernauskis K, Barauskas G, Dambrauskas Z

META-ANALYSIS

- 7791** Laparoscopic vs open hepatectomy for hepatolithiasis: An updated systematic review and meta-analysis

Li H, Zhang J, Cai JY, Li SH, Zhang JB, Wang XM, Chen GH, Yang Y, Wang GS

CASE REPORT

- 7807** Fatal gastrointestinal histoplasmosis 15 years after orthotopic liver transplantation

Agrawal N, Jones DEJ, Dyson JK, Hoare T, Melmore SA, Needham S, Thompson NP

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, kenshi Matsumoto, MD, PhD, Associate Professor, Department of Gastroenterology, Juntendo University, Tokyo 113-8421, Japan

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR
THIS ISSUE

Responsible Assistant Editor: Xiang Li
Responsible Electronic Editor: Yan Huang
Proofing Editor-in-Chief: Lian-Sheng Ma

Responsible Science Editor: Ke Chen
Proofing Editorial Office Director: Jin-Lei Wang

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Jin-Lei Wang, Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.wjgnet.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
November 21, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.wjgnet.com>

Functional interaction of endoplasmic reticulum stress and hepatitis B virus in the pathogenesis of liver diseases

So Young Kim, Yi Yi Kyaw, Jaehun Cheong

So Young Kim, Yi Yi Kyaw, Jaehun Cheong, Department of Molecular Biology, Pusan National University, Busan 609-735, South Korea

ORCID number: So Young Kim (0000-0003-4934-5248); Yi Yi Kyaw (0000-0002-3238-6900); Jaehun Cheong (0000-0002-2001-1685).

Author contributions: Kim SY and Kyaw YY prepared the manuscript; Cheong J designed and revised the manuscript.

Supported by the National Research Foundation of South Korea, No. NRF-2009-0093195; and Basic Science Research Program through the NRF funded by the Ministry of Education, No. NRF-2013R1A1A2057634.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Jaehun Cheong, PhD, Department of Molecular Biology, Pusan National University, Busan 609-735, South Korea. molecule85@pusan.ac.kr
Telephone: +82-51-5102277
Fax: +82-51-5139258

Received: April 21, 2017

Peer-review started: April 25, 2017

First decision: June 22, 2017

Revised: September 1, 2017

Accepted: November 1, 2017

Article in press: November 1, 2017

Published online: November 21, 2017

Abstract

Hepatitis B virus (HBV) is a non-cytopathic virus that causes acute and chronic inflammatory liver diseases, often leading to the pathogenesis of hepatocellular carcinoma (HCC). Although many studies for the roles of HBV on pathogenesis of the liver diseases, such as non-alcoholic fatty liver disease (NAFLD), hepatic inflammation, cirrhosis, and HCC, have been reported, the mechanisms are not fully understood. Endoplasmic reticulum (ER) and mitochondria have the protective mechanisms to restore their damaged function by intrinsic or extrinsic stresses, but their chronic dysfunctions are associated with the pathogenesis of the various diseases. Furthermore, HBV can affect intra- or extracellular homeostasis through induction of ER and mitochondrial dysfunctions, leading to liver injury. Therefore, the mechanism by which HBV induces ER or mitochondrial stresses may be a therapeutic target for treatment of liver diseases.

Key words: Liver disease; Hepatitis B virus; Hepatitis B virus X protein; Endoplasmic reticulum stress; Unfolded protein response

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Endoplasmic reticulum (ER) is the major site of protein folding and calcium storage. Beside the role of ER in protein homeostasis, it controls the cholesterol production and lipid-membrane biosynthesis as well as surviving and cell death signaling mechanisms in the cell. It is well-documented that abnormal metabolic regulation induces adverse effects in liver disorders, such as non-alcoholic steatosis hepatitis,

fibrosis, cirrhosis, and hepatocellular carcinoma which are associated with hepatitis B virus (HBV) infection. Recent animal model and human studies have showed ER stress as an emerging factors involved in the development of metabolic and liver diseases. In this review, we will summarize the crucial effects of ER stress response in the pathogenesis of HBV-induced liver diseases.

Kim SY, Kyaw YY, Cheong J. Functional interaction of endoplasmic reticulum stress and hepatitis B virus in the pathogenesis of liver diseases. *World J Gastroenterol* 2017; 23(43): 7657-7665 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i43/7657.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i43.7657>

INTRODUCTION

Hepatitis B virus (HBV), a prototype member of the *Hepadnavirus* family, is a small enveloped DNA virus with a virion diameter of 42 nm. The HBV genome is a relaxed circular, partially double-stranded DNA molecule encoding four overlapping open reading frames (ORFs), named C, S, P, and X coding for core protein, surface proteins (pre-S1, pre-S2, and S), DNA polymerase, and X protein, respectively^[1]. Of the HBV-encoded proteins, the function of hepatitis B virus X protein (HBx) is not clearly understood, but it may function as a multifunctional transactivator in HBV replication and host gene transcription through interaction with host proteins^[2]. HBV primarily infects hepatocytes and causes acute and chronic liver diseases. In particular, chronic HBV infection can lead to cirrhosis of the liver, liver failure, liver cancer, and even death. According to the report of World Health Organization (WHO), there are more than 350 million people worldwide who have chronic HBV infections and more than 780 thousand people die every year due to the acute or chronic HBV infection^[3]. To date, many studies have been reported on the molecular mechanisms for relation between HBV infection and pathogenesis of hepatic diseases, but the mechanisms are still not fully understood.

Cellular organelle is a specialized compartment enclosed by lipid bilayers within a cell and has specific functions. It is classified into major organelle such as endoplasmic reticulum (ER), Golgi apparatus, mitochondria, vacuole, and nucleus and minor organelle such as autophagosome, lysosome, peroxisome, and vesicle. Damage or dysfunction of cellular organelles by intra- or extra-cellular stress is associated with the pathogenesis of various diseases. For examples, mitochondrial dysfunction induces the diseases such as myopathy, diabetes, and multiple endocrinopathy^[4] and ER dysfunction induces the diseases such as obesity, diabetes, atherosclerosis, and cancer^[5]. Here, we review relation between the HBV-encoded proteins

and damage of cellular organelles and the influence on pathogenesis of hepatic diseases.

HBV AND INTRACELLULAR ORGANELLE

HBV-mitochondria

Mitochondria are the double membrane-bound structure and consist of five compartments with specialized functions including the outer mitochondrial membrane, the inter membrane space, the inner mitochondrial membrane, the cristae space, and matrix. Mitochondria have their own independent genome which is a single circular DNA molecule encoding 37 genes^[6]. Division and genome of mitochondria are similar to those of bacterial cell. Mitochondria play critical roles in production of cellular energy, calcium and redox homeostasis, cellular signaling, regulation of cellular metabolism and cell death, and heat production^[7-9]. Of the functions of mitochondria, the most prominent function is to synthesize cellular energy, adenosine triphosphate (ATP), which is used as a source of chemical energy for metabolism and a substrate in signaling pathways^[10].

Mitochondria are very dynamic and continually fuse and divide in response to physiological conditions. Moreover, mitochondria are fragmented as the consequence of enhanced fission during apoptosis^[11] and elongated to maintain ATP production during starvation^[12]. Many mitochondrial protein complexes are composed of nuclear or mitochondrial DNA-encoded proteins. Any imbalance in the complex assembly can lead to accumulation or aggregation of unassembled or unfolded proteins^[13]. In order to cope with the accumulation of unassembled or unfolded proteins within mitochondria, mitochondria activates the mitochondrial unfolded protein response (UPR) that up-regulates the expression of mitochondrial chaperones and proteases like ER stress response^[14]. Although the environmental conditions inducing mitochondrial stress are still not clearly understood, the accumulated evidences suggest that high levels of reactive oxygen species (ROS) or inhibition of mitochondrial genome replication and transcription can induce mitochondrial UPR^[15-17]. Unfolded proteins accumulated in matrix activate mitogen-activated protein kinase kinase (MEK)/c-Jun N-terminal protein kinase 2 (JNK2)/c-Jun pathway and protein kinase R (PKR). Activated c-Jun increases the transcription of transcription factors C/EBP homologous protein (CHOP) and CCAAT/enhancer-binding protein β (C/EBP β), and then the heterodimer of CHOP and C/EBP β activate the transcription of mitochondrial proteases and chaperons^[18]. Activated PKR phosphorylates eukaryotic translational initiation factor 2 α (eIF2 α), leading to attenuating translation similar with the protein kinase RNA-like ER kinase (PERK) pathway of ER stress response^[19]. In addition, unfolded proteins accumulated

in the intermembrane space (IMS) activate estrogen receptor and NAD-dependent deacetylase sirtuin-3 (SIRT3). Activated estrogen receptor up-regulates the transcription of nuclear respiratory factor 1 (NRF1) and mitochondrial serine protease, high-temperature requirement A2 (HTRA2), and SIRT3 pathway induces anti-oxidant machinery and mitophagy to alleviate mitochondrial stress^[20,21].

Accumulated evidences have suggested that HBx protein is associated with mitochondrial aggregation or damage. HBx protein induces an abnormal aggregation of mitochondrial structures at the periphery of nucleus, which may be eventually connected with cell death^[22]. In HBx-expressing cells, the abnormal aggregation of mitochondria is induced by the increase of microtubule-dependent dynein activity through HBx-induced p38 mitogen-activated protein kinase (MAPK) activation^[23]. Siddiqui group showed that HBx protein is associated with mitochondrial damage through interaction with voltage-dependent anion channel (HVDAC3)^[24], which is known as mitochondrial porins and form pores in the outer membranes of mitochondria^[25]. The interaction induces the alteration of mitochondrial transmembrane potential leading to generation of ROS, resulting in activation of transcription factors signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa B (NFkB)^[24,26]. The ability of HBx protein to transactivate AP-1 and NFB is abolished by positioning HBx protein in the nucleus artificially^[27]. These evidences represent the ability of HBx protein as a transactivator, which is to induce gene expression through cytoplasmic factors but not nucleus.

HBx protein can affect mitochondrial functions or cell fate by regulating gene expression or translocating a series of proteins to mitochondria, respectively. HBx down-regulates the expression of mitochondrial encoded subunit proteins of electron transport in oxidative phosphorylation, resulting in a high level of cellular ROS by impairment of electron transport^[28]. Besides, HBx down-regulates the expression of nuclear encoded genes involved in mitochondrial β -oxidation of fatty acids, resulting in a low level of cellular ATP by deficiency of energy sources^[29]. HBx translocates Raf-1 kinases involved in the Ras-induced MAPK pathway or apoptosis regulator bcl-2-associated X protein (BAX) to mitochondria, leading to hepatic cell proliferation or apoptosis, respectively^[30,31]. These evidences suggest that mitochondria dysfunction by HBx contributes to the HBV-induced pathogenesis of hepatocellular carcinoma such as proliferation, metastasis, chemoresistance and other aspects of tumorigenesis.

To date a lot of researches have reported for relation between HBx protein and mitochondrial damage. However, the research for HBx protein and mitochondrial UPR has not yet been reported. Therefore, the research to clarify correlation between HBx protein or HBx-induced mitochondrial damage and mitochondrial UPR needs to be performed in future. In addition, it will be a

worthy to research for association between HBx protein and the proteins activated by mitochondrial UPR such as SIRT3, estrogen receptor, CHOP, or C/EBP β .

HBV-ER

The endoplasmic reticulum (ER) is dynamic tubular structure and forms an interconnected network with almost every membrane-bound organelles, including mitochondria, the Golgi apparatus, endosome, peroxisome, and plasma membrane through contact sites^[32,33]. The ER acts as a sensor for intra- or extracellular stimuli and is essential for cell homeostasis. The ER is classified into rough ER and smooth ER, which are externally distinguished by ribosome, a molecular machine synthesizing biological protein. The rough ER has the ribosome binding sites, named translocon on the ER outer membrane and is involved in synthesis, folding, and glycosylation of secretory or integral membrane proteins^[34]. Therefore rough ER is well-developed in specialized secretory cells such as hepatocytes, pancreatic islet cells and immune cells. The smooth ER lacks ribosome and involved in several metabolic processes including synthesis of lipids (phospholipids and steroids), metabolism of carbohydrates, regulation of calcium concentration, detoxification of drugs^[35]. The smooth ER plays also a fundamental role in the assembly of very low density lipoprotein (VLDL) particles in liver. In addition to the above-mentioned functions, ER also participate in the following processes through contact sites with other organelles: *e.g.*, ER-mitochondria: mitochondria biogenesis, lipid exchange during biosynthesis, and Ca^{2+} transfer from ER to mitochondria^[32,35]; ER-Golgi: transport of secretory proteins and non-vesicular lipid transport^[36]; ER-endosome: regulation of the intracellular distribution of endosomes^[37]; ER-peroxisome: non-vesicular lipid transport^[38]; ER-plasma membrane: regulation of phosphatidyl inositol metabolism and non-vesicular sterol transfer^[39,40].

Of the ER functions, the proper folding and modification of proteins are the most important and best characterized function of the ER, and are processed under strict quality-control process (QCR)^[41]. QCR means that only correctly matured proteins are exported to the Golgi complex and misfolded proteins are left in the ER to complete the process or to degrade the proteins^[42]. Many ER-resident proteins such as chaperones, foldases, and lectins are involved in the QCR. Most ER chaperones are Ca^{2+} dependent and have ATPase activities. N-linked glycosylation and disulfide bond formation by foldases also play significant roles in protein maturation^[43]. Viral infection induces the synthesis of a vast amount of viral proteins, leading to protein overload in ER. Therefore, the QCR is inhibited by the various stimuli such as Ca^{2+} output, nutrient deficiency or overload, hypoxia, and viral infection. The unfolded or misfolded proteins induced by the stimuli are accumulated and aggregated in ER, leading




Figure 1 Endoplasmic reticulum stress and unfolded protein response signaling pathways. ER: Endoplasmic reticulum; BIP: Binding immunoglobulin protein; PERK: Protein kinase RNA-like ER kinase; eIF2 α : Eukaryotic translational initiation factor 2 α ; ATF4: Activating transcription factor 4; IRE1: Inositol-requiring protein 1; XBP1: X-box binding protein 1; ATF6: Activating transcription factor 6; S1P: Site 1 protease; S2P: Site 2 protease; UPR: Unfolded protein response; ERAD: ER associated degradation; CHOP: C/EBP homologous protein; P: Phosphate.

to ER stress. Fortunately, the ER has four adaptive mechanisms, named UPR, to alleviate ER stress and restore ER to its normal physiological conditions^[5,41]: (1) translational attenuation for reduction of protein load, (2) induction of the expression of ER chaperones and foldases for enhancement of folding capacity, (3) induction of the expression of ER associated degradation (ERAD) proteins for clearance of unfolded proteins, (4) induction of apoptosis for removal of cells impaired by ER stress. In mammalian cells, these four responses are regulated by the regulatory pathways as described below (Figure 1).

PERK pathway: PERK is a type I transmembrane protein located in the ER. Under a normal condition, PERK exists as a monomer, an inactive state, by binding with ER chaperone, 78kD glucose-regulated protein (GRP78)/binding immunoglobulin protein (BiP)^[44]. In response to ER stress, BiP is dissociated from PERK, which is activated through oligomerization and trans-autophosphorylation^[45]. Activated PERK phosphorylates eIF2 α , leading to translational attenuation^[45]. Interestingly, phosphorylated eIF2 α allows the translation of activating transcription factor 4 (ATF4) mRNA^[46] and ATF4 induces the expression of UPR target genes involved in amino acid metabolism, antioxidant response, and ER-stress-induced apoptosis^[47].

IRE1 pathway: Inositol-requiring protein 1 (IRE1)

is a type I transmembrane protein that has a RNase domain. Under a normal condition, IRE1 exists as a monomer by binding with BiP like PERK^[44]. In response to ER stress, BiP is dissociated from IRE1, which is activated through oligomerization and trans-autophosphorylation. Activated IRE1 triggers its RNase activity, which catalyses unconventional splicing of x-box binding protein 1 (XBP1) pre-mRNA to synthesize the active transcription factor spliced XBP1 (XBP1s)^[48]. XBP1s induces the expression of UPR target genes involved in ERAD and lipid synthesis as well as the expression of ER chaperones^[49,50].

ATF6 pathway: Unlike PERK and IRE1, activating transcription factor 6 (ATF6) is a type II transmembrane protein and a basic leucine zipper transcription factor^[51]. Under a normal condition, translocation of ATF6 to the Golgi apparatus is inhibited because Golgi-localization signal of ATF6 is covered by BiP^[52]. In response to ER stress, ATF6 is released from BiP and translocates to the Golgi apparatus^[53]. In the Golgi apparatus, ATF6 is cleaved by site 1 protease (S1P) and S2P, and then a functional fragment of ATF6 is released into the cytosol^[54]. This fragment translocates to the nucleus and induces the expression of ER chaperone, ERAD components, and XBP1^[55].

Hepatocytes have well-developed ER because liver is a highly active organ for protein and lipid synthesis. The UPR could alleviate and restore ER damaged

by extraordinary task as a protein synthesis factory. In addition to protein synthesis, ER has a variety of functions, which also are affected by physiological or pathological stress. The UPR activated by rhythmic or transient physiological conditions (e.g., feeding-fasting cycles) is sufficient to restore ER stress^[56]. However, the UPR activated by irreversible or chronic stress (e.g., viral infection and obesity) is not sufficient to restore ER stress^[56] and causes hepatic dysfunction, leading to the pathogenesis of the liver diseases including non-alcoholic fatty liver disease (NAFLD), cholestatic liver disease, insulin resistance, diabetes, viral hepatitis, and liver cancer^[57-59].

In HBV-infected cells, a vast amount of HBV surface proteins is synthesized and folded in ER during its productive life-cycle, often leading to perturbation of the ER homeostasis, resulting in ER stress. This becomes known by identifying mutant surface proteins (preS1 and preS2 mutants) accumulated in the ER of the cells, termed ground glass hepatocyte (GGH) showing a hypertrophy of ER^[60,61]. ER stress activated by HBV can lead to the expression of ER degradation enhancer, mannosidase alpha-like 1 (EDE1) involved in ERAD pathway through the activation of IRE1/XBP1 pathway^[62]. The activated ERAD pathway can limit the amount of surface proteins to alleviate ER stress and to protect the cells. Therefore, ER stress is essential for proper viral protein folding and HBV replication, enabling the chronic HBV infection. In general, autophagy is highly regulated catabolic process that removes the damaged organelles or intracellular microbial pathogens through the formation of double-membrane-bound structure called the autophagosome^[63]. However, HBV can induce autophagy *via* ER stress or HBx protein for viral replication and envelopment^[64-66]. Moreover, HBV can strategically protect itself from autophagic degradation through accumulation of immature lysosomes induced by HBx protein^[67].

In vivo it seems insufficient to induction of ER stress by only surface proteins except productive life-cycle. ER stress can be induced by the change of intracellular conditions through other viral proteins. For example, HBx protein can generate ROS and decrease mitochondrial membrane potential and cellular ATP/ADP ratio through mitochondrial damage^[29]. Although the molecular mechanisms by which HBx induces ER stress are not clearly understood, these changes by HBx protein may synergistically contribute to induction of ER stress in conjunction with surface proteins. In fact, some researchers reported that UPR or ERAD pathway are activated by HBx protein alone^[62,68]. We also reported that ER stress is induced by low intracellular glucose or ATP levels as well as HBx protein^[29].

As mentioned previously, rhythmic or transient ER stress is a protective mechanism for cell survival. However, chronic ER stress under the pathological conditions such as chronic HBV infection can cause various liver diseases. We showed that HBx up-regulates the expression of cyclo-oxygenase 2 (COX2)

and stromal cell-derived factor-1 (SDF1) through PERK-eIF2 α -ATF4 pathway and IRE1-XBP1 pathway activated by ER stress, respectively^[29,69]. COX2 converts arachidonic acid to prostaglandin (e.g., prostaglandin E2), which is an important mediator of inflammation. SDF1, a small cytokine, is strongly chemotactic for lymphocytes and induces the recruitment of immune cells into liver of HBx transgenic mice^[69]. These evidences suggest that chronic ER stress induced by HBx protein may contribute to pathogenesis of hepatic inflammation and fibrosis (Figure 2).

Cyclic AMP responsive element-binding protein H (CREBH) is an ER-resident transmembrane bZIP transcription factor and a member of old astrocyte specifically induced substance (OASIS) family which show cell- or tissue-specific expression pattern^[70]. CREBH is abundant expressed in liver and its activation mechanism is similar to that of ATF6^[70]. Activated CREBH plays critical roles in iron metabolism, triacylglycerol metabolism, hepatic gluconeogenesis and lipogenesis, and inflammation by regulating the expression of various genes as a master gene^[71-75]. Considering the published papers, activated CREBH plays essential roles in various hepatic metabolisms under physiological conditions and in hepatic inflammation and cell proliferation under pathological conditions. We showed that CREBH is activated by HBV and HBx protein as well as ER stress inducer, leading to hepatic cell proliferation by inducing the expression of oncogenic genes in cooperation with HBx protein^[75]. These evidences suggest that ER stress may be closely associated with pathogenesis of HCC in patients with chronic hepatitis B.

THERAPEUTIC IMPLICATIONS

To date, the various drugs against HBV are developed and used to treat HBV patients, e.g. lamivudine, adefovir, entecavir, and tenofovir^[76]. All of the drugs are nucleoside/nucleotide analogues that target reverse-transcriptase (RT) domain of HBV polymerase which play the essential role on viral replication^[76,77]. Although the drugs can repress the viral replication efficiently, existing virus and covalently closed circular DNA (cccDNA) are not eliminated by the drugs from the infected cells. Since HBV polymerase lacks a proofreading exonuclease activity, misincorporated bases can't be removed from newly synthesized viral genome, leading to the mutations in the progeny DNA. Therefore, the resistance for the drugs often occurs in HBV patients during long-term therapy. Besides, there are the adverse effects of the drugs, including myopathy induced by depletion of mitochondrial DNA and myonecrosis, and nephrotoxicity induced by inhibition of kidney function^[78].

In addition to nucleoside/nucleotide analogues, the non-nucleoside agents that target viral entry, protein, or replication are developing. The development of agents that target viral entry was available due to




Figure 2 Mechanisms for the pathogenesis of hepatitis B virus-induced liver diseases via mitochondrial damage and endoplasmic reticulum stress. Plus and minus symbols are up- and down-regulated responses, respectively. HBV: Hepatitis B virus; cccDNA: Covalently closed circular DNA; ER: Endoplasmic reticulum; HBx: Hepatitis B virus X protein; ROS: Reactive oxygen species; ATF4: Activating transcription factor 4; XBP1: X-box binding protein 1; ATF6: Activating transcription factor 6.

identification of sodium taurocholate cotransporting polypeptide (NTCP) known as a HBV entry receptor^[79]. Cyclosporin A and Myrcludex-B strongly inhibit HBV infection into hepatocytes by binding to NTCP on plasma membrane^[80,81]. Anti-HBV agents that inhibit the secretion of viral proteins or the interaction between core and surface proteins have been reported^[82,83]. Anti-HBV agents that inhibit the viral replication by blocking RNA packing or gene expression also have been reported^[84,85]. Sorafenib, anti-liver cancer drug, suppresses the HBV gene expression, but it induces cell death at high-dose treatment^[86,87]. On the other hand, since surface protein and HBx proteins can induce ER or mitochondria stress which lead to pathogenesis of liver diseases, the development of the agents which inhibit ER or mitochondria stress is necessary in future. The development of host-targeting anti-HBV agents makes patients expect some advantages, including the low frequency of drug resistance, the synergic effect with currently available anti-HBV agents, and supply an alternative therapy.

CONCLUSION

Under normal physiological conditions, our body has adaptive system to maintain homeostasis from various stresses. Even though faced with pathological conditions, our body can be protected from the conditions by removing and restoring the damaged cells and tissues through innate and adaptive immune

system. However, HBV has the abilities to escape from the host's immune response and even to utilize autophagy for viral replication and envelopment. The abilities facilitate chronic infection of HBV, leading to chronic ER and mitochondrial stress, resulting in the pathogenesis of various liver diseases including NAFLD, cholestatic liver disease, viral hepatitis, and liver cancer. Here we indicated the mechanisms by which HBV proteins induce the dysfunction of cellular organelles and the hepatic diseases developed by the expression of UPR target genes or by disturbance of cellular signaling pathway. From a therapeutic perspective, it will be important to understand how HBV induce ER or mitochondrial dysfunctions and understanding the mechanisms will provide new treatment options to chronic HBV patients.

REFERENCES

- 1 Liaw YF, Chu CM. Hepatitis B virus infection. *Lancet* 2009; **373**: 582-592 [PMID: 19217993 DOI: 10.1016/S0140-6736(09)60207-5]
- 2 Zhang XD, Wang Y, Ye LH. Hepatitis B virus X protein accelerates the development of hepatoma. *Cancer Biol Med* 2014; **11**: 182-190 [PMID: 25364579 DOI: 10.7497/j.issn.2095-3941.2014.03.004]
- 3 World Health Organization. [webpage on the internet]. Hepatitis B. <http://www.who.int/mediacentre/factsheets/fs204/en/>
- 4 Kasahara A, Scorrano L. Mitochondria: from cell death executioners to regulators of cell differentiation. *Trends Cell Biol* 2014; **24**: 761-770 [PMID: 25189346 DOI: 10.1016/j.tcb.2014.08.005]
- 5 Yoshida H. ER stress and diseases. *FEBS J* 2007; **274**: 630-658 [PMID: 17288551 DOI: 10.1111/j.1742-4658.2007.05639.x]
- 6 Chan DC. Mitochondria: dynamic organelles in disease, aging,

- and development. *Cell* 2006; **125**: 1241-1252 [PMID: 16814712 DOI: 10.1016/j.cell.2006.06.010]
- 7 **Li X**, Fang P, Mai J, Choi ET, Wang H, Yang XF. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. *J Hematol Oncol* 2013; **6**: 19 [PMID: 23442817 DOI: 10.1186/1756-8722-6-19]
 - 8 **Green DR**. Apoptotic pathways: the roads to ruin. *Cell* 1998; **94**: 695-698 [PMID: 9753316 DOI: 10.1016/S0092-8674(00)81728-6]
 - 9 **Hajnóczky G**, Csordás G, Das S, Garcia-Perez C, Saotome M, Sinha Roy S, Yi M. Mitochondrial calcium signalling and cell death: approaches for assessing the role of mitochondrial Ca²⁺ uptake in apoptosis. *Cell Calcium* 2006; **40**: 553-560 [PMID: 17074387 DOI: 10.1016/j.ceca.2006.08.016]
 - 10 **McBride HM**, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. *Curr Biol* 2006; **16**: R551-R560 [PMID: 16860735 DOI: 10.1016/j.cub.2006.06.054]
 - 11 **Dai J**, Wu P, Xu S, Li Y, Zhu Y, Wang L, Wang C, Zhou P, Shi H. Changes in mitochondrial ultrastructure in SH-SY5Y cells during apoptosis induced by hemin. *Neuroreport* 2017; **28**: 551-554 [PMID: 28489664 DOI: 10.1097/WNR.0000000000000790]
 - 12 **Gomes LC**, Di Benedetto G, Scorrano L. During autophagy mitochondria elongate, are spared from degradation and sustain cell viability. *Nat Cell Biol* 2011; **13**: 589-598 [PMID: 21478857 DOI: 10.1038/ncb2220]
 - 13 **Sasaki K**, Yoshida H. Organelle autoregulation-stress responses in the ER, Golgi, mitochondria and lysosome. *J Biochem* 2015; **157**: 185-195 [PMID: 25657091 DOI: 10.1093/jb/mvv010]
 - 14 **Haynes CM**, Ron D. The mitochondrial UPR - protecting organelle protein homeostasis. *J Cell Sci* 2010; **123**: 3849-3855 [PMID: 21048161 DOI: 10.1242/jcs.075119]
 - 15 **Martins RD**, Garth GP, Webster TL, Cartwright P, Naylor DJ, Høj PB, Hoogenraad NJ. Selective induction of mitochondrial chaperones in response to loss of the mitochondrial genome. *Eur J Biochem* 1996; **240**: 98-103 [PMID: 8797841 DOI: 10.1111/j.1432-1033.1996.0098h.x]
 - 16 **Cochemé HM**, Murphy MP. Complex I is the major site of mitochondrial superoxide production by paraquat. *J Biol Chem* 2008; **283**: 1786-1798 [PMID: 18039652 DOI: 10.1074/jbc.M708597200]
 - 17 **Yoneda T**, Benedetti C, Urano F, Clark SG, Harding HP, Ron D. Compartment-specific perturbation of protein handling activates genes encoding mitochondrial chaperones. *J Cell Sci* 2004; **117**: 4055-4066 [PMID: 15280428 DOI: 10.1242/jcs.01275]
 - 18 **Horibe T**, Hoogenraad NJ. The chop gene contains an element for the positive regulation of the mitochondrial unfolded protein response. *PLoS One* 2007; **2**: e835 [PMID: 17848986 DOI: 10.1371/journal.pone.0000835]
 - 19 **Rath E**, Berger E, Messlik A, Nunes T, Liu B, Kim SC, Hoogenraad N, Sans N, Sartor RB, Haller D. Induction of dsRNA-activated protein kinase links mitochondrial unfolded protein response to the pathogenesis of intestinal inflammation. *Gut* 2012; **61**: 1269-1278 [PMID: 21997551 DOI: 10.1136/gutjnl-2011-300767]
 - 20 **Papa L**, Germain D. Estrogen receptor mediates a distinct mitochondrial unfolded protein response. *J Cell Sci* 2011; **124**: 1396-1402 [PMID: 21486948 DOI: 10.1242/jcs.078220]
 - 21 **Papa L**, Germain D. SirT3 regulates the mitochondrial unfolded protein response. *Mol Cell Biol* 2014; **34**: 699-710 [PMID: 24324009 DOI: 10.1128/MCB.01337-13]
 - 22 **Shirakata Y**, Koike K. Hepatitis B virus X protein induces cell death by causing loss of mitochondrial membrane potential. *J Biol Chem* 2003; **278**: 22071-22078 [PMID: 12676947 DOI: 10.1074/jbc.M301606200]
 - 23 **Kim S**, Kim HY, Lee S, Kim SW, Sohn S, Kim K, Cho H. Hepatitis B virus x protein induces perinuclear mitochondrial clustering in microtubule- and Dynein-dependent manners. *J Virol* 2007; **81**: 1714-1726 [PMID: 17151129 DOI: 10.1128/JVI.01863-06]
 - 24 **Rahmani Z**, Huh KW, Lasher R, Siddiqui A. Hepatitis B virus X protein colocalizes to mitochondria with a human voltage-dependent anion channel, HVDAC3, and alters its transmembrane potential. *J Virol* 2000; **74**: 2840-2846 [PMID: 10684300 DOI: 10.1128/JVI.74.6.2840-2846.2000]
 - 25 **Sorgato MC**, Moran O. Channels in mitochondrial membranes: knowns, unknowns, and prospects for the future. *Crit Rev Biochem Mol Biol* 1993; **28**: 127-171 [PMID: 7683593 DOI: 10.3109/10409239309086793]
 - 26 **Waris G**, Huh KW, Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. *Mol Cell Biol* 2001; **21**: 7721-7730 [PMID: 11604508 DOI: 10.1128/MCB.21.22.7721-7730.2001]
 - 27 **Doria M**, Klein N, Lucito R, Schneider RJ. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. *EMBO J* 1995; **14**: 4747-4757 [PMID: 7588604]
 - 28 **Lee YI**, Hwang JM, Im JH, Lee YI, Kim NS, Kim DG, Yu DY, Moon HB, Park SK. Human hepatitis B virus-X protein alters mitochondrial function and physiology in human liver cells. *J Biol Chem* 2004; **279**: 15460-15471 [PMID: 14724286 DOI: 10.1074/jbc.M309280200]
 - 29 **Cho HK**, Cheong KJ, Kim HY, Cheong J. Endoplasmic reticulum stress induced by hepatitis B virus X protein enhances cyclooxygenase 2 expression via activating transcription factor 4. *Biochem J* 2011; **435**: 431-439 [PMID: 21244365 DOI: 10.1042/BJ20102071]
 - 30 **Chen J**, Siddiqui A. Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress. *J Virol* 2007; **81**: 6757-6760 [PMID: 17428866 DOI: 10.1128/JVI.00172-07]
 - 31 **Kim HJ**, Kim SY, Kim J, Lee H, Choi M, Kim JK, Ahn JK. Hepatitis B virus X protein induces apoptosis by enhancing translocation of Bax to mitochondria. *IUBMB Life* 2008; **60**: 473-480 [PMID: 18481805 DOI: 10.1002/iub.68]
 - 32 **Rowland AA**, Voeltz GK. Endoplasmic reticulum-mitochondria contacts: function of the junction. *Nat Rev Mol Cell Biol* 2012; **13**: 607-625 [PMID: 22992592 DOI: 10.1038/nrm3440]
 - 33 **Friedman JR**, Voeltz GK. The ER in 3D: a multifunctional dynamic membrane network. *Trends Cell Biol* 2011; **21**: 709-717 [PMID: 21900009 DOI: 10.1016/j.tcb.2011.07.004]
 - 34 **Görlich D**, Prehn S, Hartmann E, Kalies KU, Rapoport TA. A mammalian homolog of SEC61p and SECYp is associated with ribosomes and nascent polypeptides during translocation. *Cell* 1992; **71**: 489-503 [PMID: 1423609 DOI: 10.1016/0092-8674(92)90517-G]
 - 35 **de Brito OM**, Scorrano L. An intimate liaison: spatial organization of the endoplasmic reticulum-mitochondria relationship. *EMBO J* 2010; **29**: 2715-2723 [PMID: 20717141 DOI: 10.1038/emboj.2010.177]
 - 36 **Lev S**. Non-vesicular lipid transport by lipid-transfer proteins and beyond. *Nat Rev Mol Cell Biol* 2010; **11**: 739-750 [PMID: 20823909 DOI: 10.1038/nrm2971]
 - 37 **Rocha N**, Kuijl C, van der Kant R, Janssen L, Houben D, Janssen H, Zwart W, Neeffjes J. Cholesterol sensor ORP1L contacts the ER protein VAP to control Rab7-RILP-p150 Glued and late endosome positioning. *J Cell Biol* 2009; **185**: 1209-1225 [PMID: 19564404 DOI: 10.1083/jcb.200811005]
 - 38 **Raychaudhuri S**, Prinz WA. Nonvesicular phospholipid transfer between peroxisomes and the endoplasmic reticulum. *Proc Natl Acad Sci USA* 2008; **105**: 15785-15790 [PMID: 18836080 DOI: 10.1073/pnas.0808321105]
 - 39 **Schulz TA**, Prinz WA. Sterol transport in yeast and the oxysterol binding protein homologue (OSH) family. *Biochim Biophys Acta* 2007; **1771**: 769-780 [PMID: 17434796 DOI: 10.1016/j.bbalip.2007.03.003]
 - 40 **Stefan CJ**, Manford AG, Baird D, Yamada-Hanff J, Mao Y, Emr SD. Osh proteins regulate phosphoinositide metabolism at ER-plasma membrane contact sites. *Cell* 2011; **144**: 389-401 [PMID: 21295699 DOI: 10.1016/j.cell.2010.12.034]
 - 41 **Schröder M**, Kaufman RJ. ER stress and the unfolded protein response. *Mutat Res* 2005; **569**: 29-63 [PMID: 15603751 DOI: 10.1016/j.mbs.2005.06.001]

- 10.1016/j.mrfmmm.2004.06.056]
- 42 **Ellgaard L**, Molinari M, Helenius A. Setting the standards: quality control in the secretory pathway. *Science* 1999; **286**: 1882-1888 [PMID: 10583943 DOI: 10.1126/science.286.5446.1882]
 - 43 **Schröder M**. Endoplasmic reticulum stress responses. *Cell Mol Life Sci* 2008; **65**: 862-894 [PMID: 18038217 DOI: 10.1007/s00018-007-7383-5]
 - 44 **Bertolotti A**, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. *Nat Cell Biol* 2000; **2**: 326-332 [PMID: 10854322 DOI: 10.1038/35014014]
 - 45 **Harding HP**, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. *Nature* 1999; **397**: 271-274 [PMID: 9930704 DOI: 10.1038/16729]
 - 46 **Harding HP**, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. *Mol Cell* 2000; **6**: 1099-1108 [PMID: 11106749 DOI: 10.1016/S1097-2765(00)00108-8]
 - 47 **Harding HP**, Zhang Y, Zeng H, Novoa I, Lu PD, Calton M, Sadri N, Yun C, Popko B, Pauls R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. *Mol Cell* 2003; **11**: 619-633 [PMID: 12667446 DOI: 10.1016/S1097-2765(03)00105-9]
 - 48 **Yoshida H**, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. *Cell* 2001; **107**: 881-891 [PMID: 11779464 DOI: 10.1016/S0092-8674(01)00611-0]
 - 49 **Lee AH**, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. *Mol Cell Biol* 2003; **23**: 7448-7459 [PMID: 14559994 DOI: 10.1128/MCB.23.21.7448-7459.2003]
 - 50 **Sriburi R**, Jackowski S, Mori K, Brewer JW. XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. *J Cell Biol* 2004; **167**: 35-41 [PMID: 15466483 DOI: 10.1083/jcb.200406136]
 - 51 **Cox JS**, Shamu CE, Walter P. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. *Cell* 1993; **73**: 1197-1206 [PMID: 8513503 DOI: 10.1016/0092-8674(93)90648-A]
 - 52 **Shen J**, Chen X, Hendershot L, Prywes R. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. *Dev Cell* 2002; **3**: 99-111 [PMID: 12110171 DOI: 10.1016/S1534-5807(02)00203-4]
 - 53 **Chen X**, Shen J, Prywes R. The luminal domain of ATF6 senses endoplasmic reticulum (ER) stress and causes translocation of ATF6 from the ER to the Golgi. *J Biol Chem* 2002; **277**: 13045-13052 [PMID: 11821395 DOI: 10.1074/jbc.M110636200]
 - 54 **Shen J**, Prywes R. Dependence of site-2 protease cleavage of ATF6 on prior site-1 protease digestion is determined by the size of the luminal domain of ATF6. *J Biol Chem* 2004; **279**: 43046-43051 [PMID: 15299016 DOI: 10.1074/jbc.M408466200]
 - 55 **Yoshida H**, Okada T, Haze K, Yanagi H, Yura T, Negishi M, Mori K. ATF6 activated by proteolysis binds in the presence of NF-Y (CBF) directly to the cis-acting element responsible for the mammalian unfolded protein response. *Mol Cell Biol* 2000; **20**: 6755-6767 [PMID: 10958673 DOI: 10.1128/MCB.20.18.6755-6767.2000]
 - 56 **Fu S**, Watkins SM, Hotamisligil GS. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. *Cell Metab* 2012; **15**: 623-634 [PMID: 22560215 DOI: 10.1016/j.cmet.2012.03.007]
 - 57 **Kaplowitz N**, Than TA, Shinohara M, Ji C. Endoplasmic reticulum stress and liver injury. *Semin Liver Dis* 2007; **27**: 367-377 [PMID: 17979073 DOI: 10.1055/s-2007-991513]
 - 58 **Dara L**, Ji C, Kaplowitz N. The contribution of endoplasmic reticulum stress to liver diseases. *Hepatology* 2011; **53**: 1752-1763 [PMID: 21384408 DOI: 10.1002/hep.24279]
 - 59 **Jo H**, Choe SS, Shin KC, Jang H, Lee JH, Seong JK, Back SH, Kim JB. Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor. *Hepatology* 2013; **57**: 1366-1377 [PMID: 23152128 DOI: 10.1002/hep.26126]
 - 60 **Wang HC**, Huang W, Lai MD, Su IJ. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. *Cancer Sci* 2006; **97**: 683-688 [PMID: 16863502 DOI: 10.1111/j.1349-7006.2006.00235.x]
 - 61 **Wang HC**, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. *Am J Pathol* 2003; **163**: 2441-2449 [PMID: 14633616 DOI: 10.1016/S0002-9440(10)63599-7]
 - 62 **Lazar C**, Macovei A, Petrescu S, Branza-Nichita N. Activation of ERAD pathway by human hepatitis B virus modulates viral and subviral particle production. *PLoS One* 2012; **7**: e34169 [PMID: 22461906 DOI: 10.1371/journal.pone.0034169]
 - 63 **He C**, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy. *Annu Rev Genet* 2009; **43**: 67-93 [PMID: 19653858 DOI: 10.1146/annurev-genet-102808-114910]
 - 64 **Tang H**, Da L, Mao Y, Li Y, Li D, Xu Z, Li F, Wang Y, Tiollais P, Li T, Zhao M. Hepatitis B virus X protein sensitizes cells to starvation-induced autophagy via up-regulation of beclin 1 expression. *Hepatology* 2009; **49**: 60-71 [PMID: 19065679 DOI: 10.1002/hep.22581]
 - 65 **Sir D**, Tian Y, Chen WL, Ann DK, Yen TS, Ou JH. The early autophagic pathway is activated by hepatitis B virus and required for viral DNA replication. *Proc Natl Acad Sci U S A* 2010; **107**: 4383-4388 [PMID: 20142477 DOI: 10.1073/pnas.0911373107]
 - 66 **Li J**, Liu Y, Wang Z, Liu K, Wang Y, Liu J, Ding H, Yuan Z. Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment. *J Virol* 2011; **85**: 6319-6333 [PMID: 21507968 DOI: 10.1128/JVI.02627-10]
 - 67 **Liu B**, Fang M, Hu Y, Huang B, Li N, Chang C, Huang R, Xu X, Yang Z, Chen Z, Liu W. Hepatitis B virus X protein inhibits autophagic degradation by impairing lysosomal maturation. *Autophagy* 2014; **10**: 416-430 [PMID: 24401568 DOI: 10.4161/auto.27286]
 - 68 **Li B**, Gao B, Ye L, Han X, Wang W, Kong L, Fang X, Zeng Y, Zheng H, Li S, Wu Z, Ye L. Hepatitis B virus X protein (HBx) activates ATF6 and IRE1-XBP1 pathways of unfolded protein response. *Virus Res* 2007; **124**: 44-49 [PMID: 17092596 DOI: 10.1016/j.virusres.2006.09.011]
 - 69 **Cho HK**, Kim SY, Seong JK, Cheong J. Hepatitis B virus X increases immune cell recruitment by induction of chemokine SDF-1. *FEBS Lett* 2014; **588**: 733-739 [PMID: 24462680 DOI: 10.1016/j.febslet.2014.01.017]
 - 70 **Asada R**, Kanemoto S, Kondo S, Saito A, Imaizumi K. The signalling from endoplasmic reticulum-resident bZIP transcription factors involved in diverse cellular physiology. *J Biochem* 2011; **149**: 507-518 [PMID: 21454302 DOI: 10.1093/jb/mvr041]
 - 71 **Zhang K**, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, Back SH, Kaufman RJ. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. *Cell* 2006; **124**: 587-599 [PMID: 16469704 DOI: 10.1016/j.cell.2005.11.040]
 - 72 **Vecchi C**, Montosi G, Zhang K, Lamberti I, Duncan SA, Kaufman RJ, Pietrangelo A. ER stress controls iron metabolism through induction of hepcidin. *Science* 2009; **325**: 877-880 [PMID: 19679815 DOI: 10.1126/science.1176639]
 - 73 **Lee MW**, Chanda D, Yang J, Oh H, Kim SS, Yoon YS, Hong S, Park KG, Lee IK, Choi CS, Hanson RW, Choi HS, Koo SH. Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. *Cell Metab* 2010; **11**: 331-339 [PMID: 20374965 DOI: 10.1016/j.cmet.2010.02.016]
 - 74 **Lee JH**, Giannikopoulos P, Duncan SA, Wang J, Johansen CT, Brown JD, Plutzky J, Hegele RA, Glimcher LH, Lee AH. The transcription factor cyclic AMP-responsive element-binding protein H regulates triglyceride metabolism. *Nat Med* 2011; **17**: 812-815 [PMID: 21666694 DOI: 10.1038/nm.2347]
 - 75 **Cho HK**, Kim SY, Kyaw YY, Win AA, Koo SH, Kim HH, Cheong J. HBx induces the proliferation of hepatocellular carcinoma cells via AP1 over-expressed as a result of ER stress. *Biochem J* 2015;

- 466: 115-121 [PMID: 25428452 DOI: 10.1042/BJ20140819]
- 76 **Kim KH**, Kim ND, Seong BL. Discovery and development of anti-HBV agents and their resistance. *Molecules* 2010; **15**: 5878-5908 [PMID: 20802402 DOI: 10.3390/molecules15095878]
- 77 **Wang GH**, Seeger C. Novel mechanism for reverse transcription in hepatitis B viruses. *J Virol* 1993; **67**: 6507-6512 [PMID: 7692081]
- 78 **Fleischer RD**, Lok AS. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. *J Hepatol* 2009; **51**: 787-791 [PMID: 19665816 DOI: 10.1016/j.jhep.2009.06.011]
- 79 **Watashi K**, Urban S, Li W, Wakita T. NTCP and beyond: opening the door to unveil hepatitis B virus entry. *Int J Mol Sci* 2014; **15**: 2892-2905 [PMID: 24557582 DOI: 10.3390/ijms15022892]
- 80 **Petersen J**, Dandri M, Mier W, Lütgehetmann M, Volz T, von Weizsäcker F, Haberkorn U, Fischer L, Pollok JM, Erbes B, Seitz S, Urban S. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. *Nat Biotechnol* 2008; **26**: 335-341 [PMID: 18297057 DOI: 10.1038/nbt1389]
- 81 **Watashi K**, Sluder A, Daito T, Matsunaga S, Ryo A, Nagamori S, Iwamoto M, Nakajima S, Tsukuda S, Borroto-Esoda K, Sugiyama M, Tanaka Y, Kanai Y, Kusuvara H, Mizokami M, Wakita T. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). *Hepatology* 2014; **59**: 1726-1737 [PMID: 24375637 DOI: 10.1002/hep.26982]
- 82 **Shin MS**, Kang EH, Lee YI. A flavonoid from medicinal plants blocks hepatitis B virus-e antigen secretion in HBV-infected hepatocytes. *Antiviral Res* 2005; **67**: 163-168 [PMID: 16118024 DOI: 10.1016/j.antiviral.2005.06.005]
- 83 **Asif-Ullah M**, Choi KJ, Choi KI, Jeong YJ, Yu YG. Identification of compounds that inhibit the interaction between core and surface protein of hepatitis B virus. *Antiviral Res* 2006; **70**: 85-90 [PMID: 16487605 DOI: 10.1016/j.antiviral.2006.01.003]
- 84 **Feld JJ**, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA. The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. *Antiviral Res* 2007; **76**: 168-177 [PMID: 17709147 DOI: 10.1016/j.antiviral.2007.06.014]
- 85 **Li Y**, Fu L, Yeo H, Zhu JL, Chou CK, Kou YH, Yeh SF, Gullen E, Austin D, Cheng YC. Inhibition of hepatitis B virus gene expression and replication by helioxanthin and its derivative. *Antivir Chem Chemother* 2005; **16**: 193-201 [PMID: 16004082 DOI: 10.1177/095632020501600305]
- 86 **Rahmani M**, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P, Grant S. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. *Mol Cell Biol* 2007; **27**: 5499-5513 [PMID: 17548474 DOI: 10.1128/MCB.01080-06]
- 87 **Kim HY**, Jung HU, Yoo SH, Yoo KS, Cheong J, Park BS, Yun I, Yoo YH. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression. *Cancer Lett* 2014; **355**: 61-69 [PMID: 25218348 DOI: 10.1016/j.canlet.2014.09.015]

P- Reviewer: Chen YJ, Sazci A **S- Editor:** Gong ZM **L- Editor:** A
E- Editor: Huang Y





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

